You are here:

rosuvastatin (Crestor)

Advice

following a full submission

rosuvastatin (Crestor®) is not recommended for use within NHS Scotland.

Indication under review: Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event as an adjunct to correction of other risk factors.

In a randomised, placebo-controlled, double-blind, multi-centre study, treatment with rosuvastatin was associated with a significantly reduced risk of first cardiovascular event versus placebo in patient sub-groups deemed to be high-risk when assessed using the Framingham equation and the SCORE algorithm.

The submitting company did not present sufficiently robust economic analysis to gain acceptance by SMC.
 

Drug Details

Drug Name: rosuvastatin (Crestor)
SMC Drug ID: 725/11
Manufacturer: AstraZeneca UK Ltd
Indication: For the prevention of major cardiovascular events in patients estimated to have a high risk for a first cardiovascular event.
BNF Category:
Sub Category: 2.12 Lipid-regulating drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 10 October 2011

Back